Autonomix Medical, Inc. Granted U.S. Patent Covering Sensing Data Collection and Processing with Company's Proprietary Catheter-Based Technology
Continued progress with growing global patent portfolio to over 80 issued patents and 40 pending patent applications
Proprietary sensing and ablation technology has demonstrated potential to more precisely target and eliminate overactive nerves, improving response rates and enhancing patient outcomes across multiple indications
THE WOODLANDS, TX, March 20, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) ('Autonomix' or the 'Company'), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. patent 12,217,863 ('863 patent) titled, Medical Devices with Circuitry for Capturing and Processing Physiological Signals. The issued '863 patent gives Autonomix protection of proprietary technology used to collect and process sensing data for real-time physiological monitoring with broad application use that includes, e.g., heart mapping, arterial mapping, parenchymal monitoring, central nervous system monitoring and implant, robotic and wearable precision applications.
'We are pleased to strengthen our patent protection for this potential groundbreaking technology. The continued positive data on its application, efficacy, and safety reinforce our confidence in its potential. We remain committed to advancing this innovation to address critical areas of unmet medical need. To date, our early clinical results have been highly encouraging for reducing pancreatic cancer pain. Beyond cancer pain, our technology holds promise for a broad range of conditions where nerve activity plays a key role, including hypertension within the cardiovascular space,' commented Brad Hauser, CEO of Autonomix.
Autonomix's first-in-class technology platform utilizes a catheter-based microchip sensing array antenna that may have the ability to detect and differentiate neural signals with up to 3,000 times greater sensitivity than currently available technologies. Once target nerves are identified, Autonomix uses its proprietary RF ablation technology to kill targeted nerves, enabling a precision guided sense, treat and verify approach to addressing a number of disease categories from chronic pain management to hypertension and cardiology. Current approaches, primarily relying on opioids or invasive ethanol injections, can provide only limited relief and may lead to risky side effects.
The Company expects to submit an IDE and commence U.S. clinical trials in 2025 to support a labeling indication to commercialize the Autonomix Sensing and RF Ablation System in the U.S. as a treatment for pancreatic cancer pain.
For more information about the Company's technology, please visit autonomix.com.
About Autonomix Medical, Inc.
Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company's first-in-class platform system technology includes a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with up to 3,000 times greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body.
We are initially developing this technology for the treatment of pain, with initial trials focused on pancreatic cancer, a condition that causes debilitating pain and is without a reliable solution. Our technology constitutes a platform to address dozens of potential indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. Our technology is investigational and has not yet been cleared for marketing in the United States.
For more information, visit autonomix.com and connect with the Company on X, LinkedIn, Instagram and Facebook.
Forward Looking Statements
Some of the statements in this release are 'forward-looking statements,' which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, the potential of the technology to treat cancerous tumors and the pain associated with pancreatic cancer, to submit and receive approval of an IDE, and to file a De Novo application. Such forward-looking statements can be identified by the use of words such as 'should,' 'might,' 'may,' 'intends,' 'anticipates,' 'believes,' 'estimates,' 'projects,' 'forecasts,' 'expects,' 'plans,' and 'proposes.'
Although Autonomix believes that the expectations reflected in these forward-looking statements are based on reasonable assumptions, there are a number of risks and uncertainties that could cause actual results to differ materially from such forward-looking statements. You are urged to carefully review and consider any cautionary statements and other disclosures, including the statements made under the heading 'Risk Factors' and elsewhere in the Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on May 31, 2024, and from time to time, our other filings with the SEC. Forward-looking statements speak only as of the date of the document in which they are contained and Autonomix does not undertake any duty to update any forward-looking statements except as may be required by law.
Investor and Media Contact
JTC Team, LLCJenene Thomas 908.824.0775 autonomix@jtcir.comSign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
12 minutes ago
- Yahoo
Nevada health bill advances to Gov. Lombardo's desk
LAS VEGAS (KLAS) – Health bill SB 217 advanced in the Nevada legislature last week and is now on Governor Lombardo's desk awaiting his signature. The bill includes coverage for treatments like IVF, as well as fertility preservation for those who have been diagnosed with extreme illness. 'I had arthritis for most of my life. That drug that I was on, while helpful to my arthritis, was severely damaging to my egg reserves,' shared Stephanie Capellas-Glascock, who has been struggling with her infertility journey for years. 'I knew that it wasn't going to be something that I could accomplish on my own, so therefore I needed to look into fertility treatments for myself,' she explained. If signed, Nevada could become the first state in the nation to offer fertility coverage for Medicaid. However, the bill does face pushback for its cost and certain language in it. 'One of my concerns, just looking at it, so I may reserve my right to change my vote, is just the financial impact on our public employee benefit program that can go down to increasing premiums,' said Democratic Assembly Member Shea Backus, who did vote in favor. Meanwhile, the Nevada GOP party called on the governor to veto the bill. Their website cited their opposition because it 'declares embryos prior to implantation as non-human.' 'I don't think fertility treatments are a political issue. I think it's a health and medical issue,' Capellas-Glascock responded when asked about the opposition. 'We know that the GOP has some thoughts and feelings on that too, but I think the tremendous thing about IVF is that it is a miracle in medicine and science that really affords individuals the option to have a family, so when they're ready to start a family, they have that option.' When asked about the fiscal implications, she responded, 'There's always a cost associated. I think it's knowing that the pros supremely outweigh the cons.' The state estimated the cost would be about $38 million over the next two years. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
27 minutes ago
- Yahoo
Krystal hosting in-person hiring event for new Walterboro location
WALTERBORO, S.C. (WCBD) – Krystal is looking for employees to work at the burger chain's soon-to-open Walterboro location. The Georgia-based fast food spot will host an in-person hiring event on Wednesday, June 11, from 11 a.m. to 5 p.m. at 1222 Bells Highway, the site of the new location. Officials said the crew hopes to hire 40 new team members for all interested should bring a valid ID and their Social Security number. No prior experience is required. 'As we grow in South Carolina, our focus is on creating meaningful connections with our guests and our team,' said Amanda Hyde, Senior Vice President of Operations for Krystal. 'That means more than great food. It's about greeting guests by name, handing over every order with care, and creating an environment where team members feel empowered to deliver true hospitality.' The restaurant is expected to open officially in July, although an exact date has yet to be announced. Once open, the Walterboro site will be Krystal's fifth South Carolina location. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
33 minutes ago
- Yahoo
BHP Group Limited (ASX:BHP) is favoured by institutional owners who hold 55% of the company
Significantly high institutional ownership implies BHP Group's stock price is sensitive to their trading actions A total of 25 investors have a majority stake in the company with 48% ownership Recent purchases by insiders Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. Every investor in BHP Group Limited (ASX:BHP) should be aware of the most powerful shareholder groups. And the group that holds the biggest piece of the pie are institutions with 55% ownership. Put another way, the group faces the maximum upside potential (or downside risk). Since institutional have access to huge amounts of capital, their market moves tend to receive a lot of scrutiny by retail or individual investors. As a result, a sizeable amount of institutional money invested in a firm is generally viewed as a positive attribute. In the chart below, we zoom in on the different ownership groups of BHP Group. See our latest analysis for BHP Group Institutional investors commonly compare their own returns to the returns of a commonly followed index. So they generally do consider buying larger companies that are included in the relevant benchmark index. BHP Group already has institutions on the share registry. Indeed, they own a respectable stake in the company. This suggests some credibility amongst professional investors. But we can't rely on that fact alone since institutions make bad investments sometimes, just like everyone does. It is not uncommon to see a big share price drop if two large institutional investors try to sell out of a stock at the same time. So it is worth checking the past earnings trajectory of BHP Group, (below). Of course, keep in mind that there are other factors to consider, too. Institutional investors own over 50% of the company, so together than can probably strongly influence board decisions. Hedge funds don't have many shares in BHP Group. The company's largest shareholder is State Street Global Advisors, Inc., with ownership of 7.1%. In comparison, the second and third largest shareholders hold about 6.0% and 5.7% of the stock. Our studies suggest that the top 25 shareholders collectively control less than half of the company's shares, meaning that the company's shares are widely disseminated and there is no dominant shareholder. Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. Quite a few analysts cover the stock, so you could look into forecast growth quite easily. The definition of an insider can differ slightly between different countries, but members of the board of directors always count. The company management answer to the board and the latter should represent the interests of shareholders. Notably, sometimes top-level managers are on the board themselves. Most consider insider ownership a positive because it can indicate the board is well aligned with other shareholders. However, on some occasions too much power is concentrated within this group. Our most recent data indicates that insiders own less than 1% of BHP Group Limited. However, it's possible that insiders might have an indirect interest through a more complex structure. Being so large, we would not expect insiders to own a large proportion of the stock. Collectively, they own AU$60m of stock. In this sort of situation, it can be more interesting to see if those insiders have been buying or selling. The general public-- including retail investors -- own 40% stake in the company, and hence can't easily be ignored. While this group can't necessarily call the shots, it can certainly have a real influence on how the company is run. It's always worth thinking about the different groups who own shares in a company. But to understand BHP Group better, we need to consider many other factors. For example, we've discovered 2 warning signs for BHP Group (1 is significant!) that you should be aware of before investing here. But ultimately it is the future, not the past, that will determine how well the owners of this business will do. Therefore we think it advisable to take a look at this free report showing whether analysts are predicting a brighter future. NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
